Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO)
- PMID: 28338705
- PMCID: PMC5582633
- DOI: 10.1093/ije/dyw152
Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO)
Conflict of interest statement
H.M.C.: research support and honorarium and member of advisory panels and speaker’s bureaus for Sanofi Aventis, Regeneron, and Eli Lilly; Advisory Panel for Novartis Pharmaceuticals; research support from Roche Pharmaceuticals, Pfizer Inc., Boehringer Ingelheim, and AstraZeneca LP; shareholder of Roche Pharmaceuticals and Bayer. R.S.L: member of advisory panels for Novo Nordisk and Eli Lilly; research support from Novo Nordisk, Eli Lilly and GlaxoSmithKline. The other authors declare no conflict of interest.
References
-
- Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373:2027–33. - PubMed
-
- So H-C, Gui AHS, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol. 2011;35:310–17. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
